Sunday, November 1, 2009

VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted




BNET Pharma provides daily industry trends and news coverage with insights for managers and executives about major manufacturers of pharmaceuticals and medicine. In addition to detailed drug company profiles, we bring you industry analysis on new partnerships, drug patents and products, cost management, investments, pharmaceutical related lawsuits, and a host of other important business issues.



VeriChip TV Ad Confirms Critics' Fears: They Want Everyone Implanted



VeriChip’s TV ad for its Health Link implantable microchip that connects to your online medical records has spawned a backlash on YouTube. Observers regard it as either part of President Obama’s secret Nazi plan to enslave us all or a sign of the coming antichrist.

The ad itself comes on like all drug advertising does — healthy, smiling middle-aged people describing the things about life they are thankful for.

But, to give VeriChip’s critics some credit, the ad clearly positions the VeriChip as something for everyone, not merely patients who are so deranged or damaged that having a chip to transmit accurate data might be useful.

VeriChip Joins Up with Diabetes Research Institute



VeriChip Corporation [[CHIP]], which has developed a system to identify people who enter an emergency room without being able to communicate, announced that it has entered into a strategic partnership with the Diabetes Research Institute to combine efforts on the further development of its glucose-sensing radio frequency identification microchip.

VeriChip and DRI intend to recreate a prospective, randomized, comparative clinical study that will seek to address the lack of appropriate, concise, and up-to-date patient health information available to both practitioners caring for diabetic patients and the patients themselves through utilization of the company’s interoperable personal health record, Health Link, system.

VeriChip to Collaborate with Diabetes Research Institute



Oct 27, 2009 (Close-Up Media via COMTEX) -- CHIP | Quote | Chart | News | PowerRating -- VeriChip Corp. has announced that it has entered into a strategic partnership with the Diabetes Research Institute (DRI) to combine efforts on the further development of the glucose-sensing radio frequency identification (RFID) microchip in conjunction with VeriChip's development partner, Receptors.

VeriChip and DRI said that they also intend to create a prospective, randomized, comparative clinical study that will seek to address the lack of appropriate, concise, and up-to-date patient health information available to both practitioners caring for diabetic patients and the patients themselves through the utilization of VeriChip's interoperable personal health record, Health Link, and an electronic medical record system.

Robert Pearlman, President and CEO of the DRI Foundation, said, "We are pleased to partner with VeriChip on this important initiative to develop a glucose-sensing RFID microchip, which could potentially improve patient care and compliance among individuals with diabetes. Furthermore, we believe access to a personal health record is vital for all patients, but particularly those with chronic illnesses. Our relationship with VeriChip will enable us to provide that access to our patients and study the utility of Health Link and the role it plays within a larger electronic medical record system."

VeriChip previously announced in November 2008 that Receptors completed Phase I of the development of the glucose-sensing RFID microchip, which demonstrated the proof-of-concept foundation of the glucose-sensing system. The companies expect Phase II will demonstrate a glucose concentration response in the presence of blood and interstitial fluid matrix components. The companies published a white paper entitled, "Development of an Implantable Glucose Sensor," which outlines the product's development and is available at verichipcorp.com.

VeriChip Corp., headquartered in Delray Beach, Florida, has developed the VeriMed Health Link System for identifying people who arrive in an emergency room and are unable to communicate.

((Comments on this story may be sent to health@closeupmedia.com))
For full details on Verichip Corporation (CHIP) click here. Verichip Corporation (CHIP) has Short Term PowerRatings of 7. Details on Verichip Corporation (CHIP) Short Term PowerRatings is available at This Link.

VeriChip Corporation to Present its Glucose-Sensing RFID Microchip and Virus Triage Detection System for the H1N1 Virus at ID World International

VeriChip Corporation (NASDAQ:CHIP) ("VeriChip" or the "Company") announced today that its Chairman and Chief Executive Officer, Scott R. Silverman, will present at the ID World International Congress in Milan, Italy, which runs from November 3-5, 2009, and is the world's leading symposium on the future directions of identification technology. Mr. Silverman will discuss, among other things, the Company's in vivo glucose-sensing RFID microchip and virus triage detection system for the H1N1 virus. There will be more than 150 speakers at ID WORLD 2009, including visionaries, CEOs, key end users and government representatives from all continents, and thousands of attendees from across the globe.

The ID WORLD International Congress is the most comprehensive showcase on the evolving world of RFID, biometrics and smart card technologies, and is the only international forum that looks at the automatic identification industry as a whole, rather than focusing on a specific technology or vertical sector. It offers a full-scale and complete vision of social, technological and business aspects related to the deployment of the automatic identification systems. The ID WORLD International Congress has consolidated its position as the most comprehensive and highly targeted global summit on automatic identification.

About VeriChip Corporation

VeriChip Corporation, headquartered in Delray Beach, Florida, has developed the VeriMed™ Health Link System for rapidly and accurately identifying people who arrive in an emergency room and are unable to communicate. This system uses the first human-implantable passive RFID microchip and corresponding personal health record, cleared for medical use in October 2004 by the United States Food and Drug Administration.

On September 8, 2009, VeriChip Corporation announced it agreed to acquire Steel Vault Corporation (OTCBB: SVUL) to form PositiveID Corporation. PositiveID will provide identification technologies and tools to protect consumers and businesses. The companies expect the merger to close in the fourth quarter of 2009.

For more information on VeriChip, please call 1-800-970-2447, or e-mail info@verichipcorp.com. Additional information can be found online at www.verichipcorp.com.

Statements about VeriChip’s future expectations, including its development of an in vivo glucose-sensing RFID microchip and a virus triage detection system for the H1N1 virus, the expectation that the merger will close in the fourth quarter of 2009, and all other statements in this press release other than historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and VeriChip’s actual results could differ materially from expected results. These risks and uncertainties include the Company’s ability to successfully develop and commercialize the microchip, the market acceptance of the microchip, the Company’s and RECEPTORS’ ability to develop a microchip, the validity, scope and enforceability of the Company’s patents and those related to the microchip, the protection afforded by the Company’s patents and those related to the microchip, the Company’s ability to complete the development phases in certain time frames, government regulations relating to the microchip, the Company’s ability to fund the continued development of the microchip, the timing and success of submission, acceptance and approval of required regulatory filings; as well as certain other risks. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s various filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on February 12, 2009, under the caption “Risk Factors.” The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Additional Information and Where to Find It

On September 8, 2009, VeriChip and Steel Vault issued a joint press release announcing the signing of an Agreement and Plan of Reorganization, among VeriChip, Steel Vault and VeriChip Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of VeriChip (the “Acquisition Subsidiary”), pursuant to which the Acquisition Subsidiary will be merged with and into Steel Vault, with Steel Vault surviving and becoming a wholly-owned subsidiary of VeriChip (the “Merger”). Upon the consummation of the Merger, each outstanding share of Steel Vault’s common stock will be converted into 0.5 shares of VeriChip common stock.

In connection with the Merger, VeriChip filed with the Securities and Exchange Commission (“SEC”) a Registration Statement on Form S-4 that will contain a Joint Proxy Statement/Prospectus of VeriChip and Steel Vault. Investors and security holders are urged to read the Registration Statement and the Joint Proxy Statement/Prospectus carefully because they contain important information about VeriChip, Steel Vault and the proposed transaction. The Joint Proxy Statement/Prospectus and other relevant materials (when they become available), and any other documents filed with the SEC, may be obtained free of charge at the SEC’s web site (www.sec.gov). In addition, investors and security holders may obtain a free copy of other documents filed by VeriChip or Steel Vault by directing a written request, as appropriate, to VeriChip at 1690 South Congress Avenue, Suite 200 Delray Beach, Florida 33445, Attention: Investor Relations, or to Steel Vault at 1690 South Congress Avenue, Suite 200 Delray Beach, Florida 33445, Attention: Investor Relations. Investors and security holders are urged to read the Joint Proxy Statement/Prospectus and the other relevant materials before making any voting or investment decision with respect to the proposed transaction.

VeriChip, Steel Vault and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction.

Information regarding the interests of these directors and executive officers in the proposed transaction will be included in the Joint Proxy Statement/Prospectus referred to above. Additional information regarding the directors and executive officers of VeriChip is also included in VeriChip's Form 10-K, which was filed with the SEC on February 12, 2009. Additional information regarding the directors and executive officers of Steel Vault is also included in Steel Vault's proxy statement (Form DEF 14A) for the 2009 annual meeting of Steel Vault's stockholders, which was filed with the SEC on February 9, 2009, as amended. These documents are available free of charge at the SEC’s website (www.sec.gov) and by contacting Investor Relations at the addresses above.

Monday, October 19, 2009

Verichipcorp Tv ad hope you like

Welcome to Cyberdyne Systems


Hello My name is Miles Bennett Dyson I Have Just found out i work for a new team. I work for Verichip corp i will tell you every thing you need to know to survive the New World order i tried to take down skynet but this is bigger then skynet We are dealing with peoples lives.